Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.

Ann Rheum Dis · 2020 · PMC7509526 · PMID 32620597

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

5–7 IL-6 blockade with sarilumab was generally safe and associated with a low mortality rate, which however did not reach statistical significance when compared with what observed in a concomitant group of patients treated with standard of care alone.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.